key: cord-0793476-8nsp6hbm
authors: Wang, Elizabeth Wenqian; Parchem, Jacqueline G; Atmar, Robert L; Clark, Eva
title: SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision
date: 2021-04-10
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab180
sha: 46b09d1fc5ab3baf01d1d152d2e9ef08d1200893
doc_id: 793476
cord_uid: 8nsp6hbm

As the first Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines passed United Kingdom and United States regulatory milestones in late 2020 and early 2021, multiple professional societies offered recommendations to assist pregnant and breastfeeding people as they choose whether to undergo vaccination. Despite such guidance, the lack of data describing vaccine safety, immunogenicity, and efficacy in pregnant and breastfeeding people has made this decision challenging for many. However, even considering the paucity of data, the known risks of Coronavirus Disease 2019 (COVID-19) during pregnancy likely outweigh the not yet fully elucidated risks of SARS-CoV-2 vaccines, which have reassuring safety and efficacy profiles among non-pregnant people.

3 Essential workers and high-risk individuals in the United Kingdom and the United States began receiving doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines en masse as the first vaccine candidates obtained emergency use authorization in December 2020. While the safety, immunogenicity, and efficacy data for the four authorized vaccines are reassuring so far [1] [2] [3] [4] , none of these vaccines has been systematically studied in pregnant and breastfeeding people, despite evidence that pregnancy may increase the risk of developing severe Coronavirus Disease 2019 and related complications. In the United States, approximately 10% of pregnant people with COVID-19 have severe or critical illness [5, 6] , and their in-hospital mortality is significantly higher compared to non-pregnant people of similar age [7] . The decision of whether to undergo SARS-CoV-2 vaccination during pregnancy is complex and causes apprehension among those considering vaccination [8] . Here, we discuss the risks and benefits of SARS-CoV-2 vaccination in pregnancy that may influence the decision-making process.

It is unclear whether pregnant people are more susceptible to SARS-CoV-2 infection than nonpregnant people. Many pregnant people infected with SARS-CoV-2 are asymptomatic (ranging from 44 to 86% in cohort studies with universally tested pregnant populations [9] [10] [11] ). While the risk of mortality is low and comparable to that of the nonpregnant population (0.1-0.2%), preexisting comorbidities, higher maternal age, and higher body mass index are risk factors for severe in pregnancy [12] [13] [14] [15] . Pregnant people who develop COVID-19 are more likely to require intensive care and have severe cardiopulmonary complications than their nonpregnant counterparts [13, 15, 16] (though these studies had several limitations; for instance, in the US Centers for Disease and Prevention [CDC] reports, pregnancy status and information on symptoms and underlying conditions were missing from more than 50% of cases [13, 15] [7] . Additionally, some studies have suggested that pregnant people with COVID-19 have an increased risk of delivering premature and/or low birthweight infants, post-partum hemorrhage, and complications requiring caesarean delivery [10, 11, [17] [18] [19] . Vertical transmission of SARS-CoV-2 certainly occurs (both in utero, which is uncommon, and peripartum), though infected infants tend to have asymptomatic disease or only mild symptoms [20, 21] .

Furthermore, pregnant people who develop COVID-19 in low resource settingswhere pregnancy outcomes are already poorer due to prevalent comorbidities, coinfections, and socioeconomic and health system inequalitiesoften lack access to effective medications and high levels of supportive care [22, 23] .

Exclusion of pregnant people from vaccine trials has been an longstanding problem [24] . Their exclusion has resulted in vaccine recommendations for pregnant women based on little data (e.g., as for the initial recommendations for inactivated influenza vaccines [25] , though subsequently robust clinical trials supported these recommendations) or recommendations only being given once "enough" pregnant people have been inadvertently vaccinated (e.g., as for MenAfriVac, a meningococcal A conjugate vaccine [26] ). Since 2018, both governmental and independent advisory groups have published recommendations advocating for the early inclusion of pregnant people in the development and deployment of vaccines against emerging pathogens [27, 28] . Subsequently, during the rapid emergence of SARS-CoV-2, many authorities advocated for inclusion of pregnant people in SARS-CoV-2 vaccine trials [29, 30] . Despite this expert guidance and the potentially devastating consequences of SARS-CoV-2 infection, pregnant people were explicitly excluded from SARS-CoV-2 vaccine clinical trials. Consequently, to date there are little published data describing the safety or efficacy of any SARS-CoV-2 vaccine in human pregnancy.

Historically, protein-based vaccines (which are non-replicating) have been considered safe in pregnancy, for both mother and fetus. In fact, the CDC's Advisory Committee on Immunization Practices (ACIP) recommends routine influenza and Tdap vaccination of all pregnant women as these vaccines are safe and induce maternal antibodies that are passed to the child in utero and via breastfeeding, thereby protecting the child from the diseases targeted by these vaccines The Oxford/AstraZeneca vaccine also requires two doses, while the Janssen vaccine is authorized for use as a single dose vaccine. In contrast to conventional protein-based vaccines, these nucleic acidbased vaccines provide genetic blueprints that allow the recipient's own cells to produce the target antigen. Theoretical concerns have been suggested regarding the potential for host genome insertion and mutagenesis of vaccine genetic material. However, these concerns are unsubstantiated by scientific evidence; the SARS-CoV-2 genetic material carried by these vaccines is not infectious, does not incorporate into the recipient's genome, and levels of vaccine mRNA/DNA and associated protein decline over several days post-vaccination as they are degraded by normal host cellular processes [36, 37] . Research on nanoparticle and adenovirus-vectored vaccines has been ongoing for decades [36, 37] . Specifically, human adenovirus serotype 26 (Ad26, which is the Janssen vaccine vector) has been used as a vector for other vaccines deemed safe for the general public, including the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine that was approved in Europe in 2020, as well as investigational vaccines against Zika, filovirus, HIV, HPV, malaria, and respiratory syncytial virus.

No adverse pregnancy outcomes have been reported for these vaccines. However, the current COVID-6 19 pandemic era is the first time that these vaccine types are being widely distributed among the general population.

Though pregnant individuals were excluded from initial clinical trials of the four vaccines authorized to date, these trials do provide information on adverse effects unrelated to pregnancy, which are important for pregnant people to consider prior to vaccination. In these trials, reports of serious adverse effects were rare (most notably, three cases of transverse myelitis were reported during the AstraZeneca/Oxford vaccine clinical trials but were thought unlikely to be related to the vaccine after independent safety committee review [38] has not yet publicly disclosed information on whether pregnancies were reported during their clinical trials.

Though the small numbers of pregnant people discussed above were inadvertently enrolled in the SARS-CoV-2 vaccine clinical trials, the information generated by their follow-up is unlikely to provide conclusive evidence regarding vaccine safety or efficacy. Because pregnancy poses unique safety concerns, it is essential that pregnant people are included in appropriately designed vaccine trials. Pfizer recently announced that they will perform a global Phase 2/3 trial to evaluate the safety, tolerability and immunogenicity of SARS-CoV-2 vaccine in pregnant people who are 18 years and older [39] . The trial is a randomized, placebo-controlled, observer-blind study of 4,000 healthy women vaccinated between 24 to 34 weeks of gestation. Each woman will participate in the study for seven to ten months, depending on whether randomized to receive vaccine or placebo, and their infants will be monitored to six months of age. Moderna has created a registry of pregnant vaccinees and is planning a prospective observational study to assess obstetric, neonatal, and infant outcomes [40] . Janssen is planning a phase 2 placebo-controlled trial in more than 800 pregnant people [41] .

AstraZeneca's plans for clinical trials in pregnant people are still uncertain. It is important that these trials move forward to evaluate the remaining unknown issues related to pregnancy such as vaccine safety and immunogenicity (including rates of antibody transfer to neonates). However, potential problems with this delayed approach to inclusion of pregnant people in vaccine clinical trials include reported were not related to pregnancy. Of the pregnancy-related adverse events, miscarriage was reported most frequently (in 29 participants); however, the reported miscarriage numbers reflect background rates [43] . The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has a similar post-vaccination registry and has also found no safety concerns in pregnant people during their data analysis [44] .

The obvious advantage to SARS-CoV-2 vaccination is protection of pregnant peopleand, to some extent, their neonatesfrom the potentially devastating complications of SARS-CoV-2 infection. In [38] ), and 66.9% for the Janssen vaccine [35] . Efficacies are likely to be similarly robust in pregnant populations. Prospective studies have already described SARS-CoV-2 vaccine-induced immune responses in pregnant and lactating people, with even higher antibody titers than those induced by SARS-CoV-2 infection during pregnancy [45] . From a public health perspective, broad vaccine uptake (i.e., an estimated 55-82% of the population) is needed to achieve effective population immunity [46] , which undoubtedly will take some time. Vaccinating as many people as possible, including pregnant and breastfeeding people, will help attain such levels more quickly. Finally, many essential workers, particularly those who are currently pregnant, have anxiety about acquiring SARS-CoV-2 infection and transmitting the virus to family, patients, and co-workers

[8]; vaccination would likely ameliorate these anxieties and provide welcomed relief and peace of mind for many.

While mRNA nanoparticle and adenovirus vector SARS-CoV-2 vaccines are not thought to pose significant risk to the recipient's fetus, important questions regarding fetal risk are only beginning to be answered [47, 48] . For instance, whether intact vaccine particles cross the placenta and enter fetal cells remains largely unknown, though studies of other lipid nanoparticle platforms suggest that they do not cross to the fetus [49] . The publication of pre-clinical DART study data and small human studies are helping to clarify such issues. For instance, one study evaluated six women after receipt of mRNA-based vaccines (five received Pfizer/BioNTech and one received Moderna/NIH) and found no evidence of vaccine mRNA in breast milk samples collected within two days of vaccination [50] .

Regarding whether maternal SARS-CoV-2 immunization leads to transfer of specific antibodies to infants, one study of 20 mother-infant pairs demonstrated efficient transplacental transfer of anti-SARS-CoV-2 spike antibodies after antenatal vaccination with the Pfizer/BioNTech vaccine [51] , and another showed presence of vaccine-derived IgA antibodies in breastmilk three to four weeks postvaccination with the Pfizer/BioNTech (n=14) and Moderna (n=9) vaccines [52] . In the latter study, IgA antibody titers in breastmilk were similar to those of participants who had experienced natural SARS-CoV-2 infection. Such findings should encourage vaccination of breastfeeding people, among whom any theoretical risks related to vaccination are likely the same as those of the general population. Additionally, both Pfizer and Moderna are conducting clinical trials of their vaccines in children, and Janssen plans to start clinical trials in adolescents in March 2021, which will yield needed data on the safety, immunogenicity, and efficacy in these populations.

The paucity of data on SARS-CoV-2 vaccines in pregnant and breastfeeding populations makes counseling patients challenging. Many regulatory agencies in the UK and the US have made recommendations regarding SARS-CoV-2 vaccination in pregnancy (Table 1) . Advisory bodies in the UK, such as the MHRA and the Royal College of Obstetricians and Gynaecologists (RCOG) initially advised against offering SARS-CoV-2 vaccines to people who are pregnant and breastfeeding, due to lack of safety data in these populations [53] , but updated their positions on December 30, 2020 [54] , to recommend consideration of vaccination in those who are frontline personnel or those who have underlying conditions that make them high risk of being infected with or experiencing serious complications of COVID-19, which includes pregnancy [54] . In contrast, the CDC's ACIP advises allowing all pregnant and breastfeeding people to choose whether to be vaccinated [21] , and, in the CDC's recommendations for prioritization of SARS-CoV-2 vaccine allocation, pregnancy is included as a "high risk" condition eligible for vaccination during Phase 1C [55] . should not be withheld from pregnant and breastfeeding people who are otherwise eligible [56] .

Clearly, with all the above data (and lack thereof) and factors to consider, the decision of whether to undergo SARS-CoV-2 vaccination during pregnancy or while breastfeeding is a complex one.

Healthcare provider counselling of pregnant people should focus on the available vaccine safety and efficacy data in the context of the individual's personal risk of SARS-CoV-2 exposure, underlying medical conditions, and SARS-CoV-2 prevalence in the community.

Several of the advisory bodies mentioned have published guides for counselling pregnant and lactating people as they contemplate the pros and cons of vaccination (e.g., a "conversation guide" from ACOG can be found here: https://www.acog.org/-/media/project/acog/acogorg/files/pdfs/clinical-guidance/practice-advisory/covid19vaccineconversationguide-121520-v2.pdf?la=en&hash=439FFEC1991B7DD3925352A5308C7C42, and 

Because pregnant people were explicitly excluded from SARS-CoV-2 vaccine clinical trials, little data are available to guide them as they decide whether to undergo SARS-CoV-2 vaccination. Even so, given the reassuring safety and efficacy profiles of the SARS-CoV-2 vaccines that have gained UK/US regulatory authorization to date, the known risks of COVID-19 likely outweigh the unclear risks of SARS-CoV-2 vaccines for pregnant and breastfeeding people. Going forward, every effort should be made to collect data on the safety, immunogenicity, and efficacy of SARS-CoV-2 vaccines in pregnant and breastfeeding people through well-designed clinical trials that include these populations. As a matter of expediency, even when pregnant people are not included in initial vaccine clinical trials, once vaccine safety and immunogenicity are established in the general population, pregnant people should be included in vaccine studies as early as possible. In the meantime, it is important to remain transparent about the lack of information, acknowledge concerns, and to support those who decide to defer vaccination until more data are available.

No author has a potential conflict of interest or funding source. 

Efficacy and Safety of the mRNA-1273

SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State

Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19)

Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19

Universal Screening for SARS-CoV-2 in Women Admitted for Delivery

Association of SARS-CoV-2 Test Status and Pregnancy Outcomes

Racial-ethnic disparities and pregnancy outcomes in SARS-CoV-2 infection in a universally

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis

Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Pregnant women with SARS-CoV-2 infection are at higher risk of death and severe pneumonia: propensity scorematched analysis of a nationwide prospective cohort study (COV19Mx)

Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic

Changes in Preterm Birth Phenotypes and Stillbirth at 2 Philadelphia Hospitals During the SARS-CoV-2 Pandemic

Stillbirths During the COVID-19 Pandemic in England

Entry, egress and vertical transmission of SARS-CoV-2

Vaccination Considerations for People who are Pregnant or Breastfeeding

The Changing Aspects of Motherhood in Face of the COVID-19 Pandemic in Low-and Middle-Income Countries. Matern Child Health J

Effect of SARS-CoV-2 Infection in Pregnancy on Maternal and Neonatal Outcomes in Africa: An AFREhealth Call for Evidence through Multicountry Research Collaboration

Ethical Considerations for Including Women as Research Participants. Available at

Global vaccine safety: Meningococcal A conjugate vaccine during pregnancy

Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response

Roehr CC, den Boer MC. Inclusion of children and pregnant women in COVID-19 intervention trials

COVID-19 vaccines and neglected pregnancy

Accessed March 18. 32. Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020: FDA Briefing Document, Pfizer-BioNTech COVID-19 Vaccine

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

FDA Briefing Document, Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19

mRNA vaccines -a new era in vaccinology

Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines

Oxford-AstraZeneca COVID-19 vaccine efficacy

Frequently Asked Questions: What is known about the safety of the vaccine for special populations (children, pregnant women, elderly people)? Available at

Pregnant People's Paradox-Excluded From Vaccine Trials Despite Having a Higher Risk of COVID-19 Complications

COVID-19 vaccine safety update: Advisory Committee on Immunization Practices (ACIP)

COVID-19 vaccine response in pregnant and lactating women: a cohort study

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know

COVID-19 vaccines in pregnancy

Liposomes: a nanoscale drug carrying system to prevent indomethacin passage to the fetus in a pregnant mouse model

COVID-19 mRNA vaccine is not detected in human milk

Efficient maternofetal transplacental transfer of anti-SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination

Immune response during lactation after anti-SARS-CoV2 mRNA vaccine

Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding

Evidence Table for COVID-19 Vaccines Allocation in Phases 1b and 1c of the Vaccination Program

Joint Statement Supporting Public Health Measures to Combat COVID-19